Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis - 24/04/13
Correspondence to: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.Abstract |
Background |
In the treatment of psoriasis, patient adherence to oral medications is poor and even worse for topical therapy. However, few data exist about adherence rates to home phototherapy, adding to concerns about the appropriateness of home phototherapy as a psoriasis treatment option.
Objective |
We sought to assess adherence to both oral acitretin and home ultraviolet B phototherapy for the treatment of psoriasis.
Methods |
In all, 27 patients with moderate to severe psoriasis were treated with 10 to 25 mg of acitretin daily, combined with narrowband ultraviolet B, 3 times weekly at home, for 12 weeks. Adherence to acitretin was monitored by an electronic monitoring medication bottle cap, and to phototherapy by a light-sensing data logger.
Results |
Adherence data were collected on 22 patients for acitretin and 16 patients for adherence to ultraviolet B. Mean adherence to acitretin decreased steadily during the 12-week trial (slope −0.24), whereas mean adherence to home phototherapy remained steady at 2 to 3 d/wk. Adherence was similar between patients who reported side effects and those who did not.
Limitations |
Small sample size and lack of follow-up on some patients were limitations of this study.
Conclusions |
Adherence rates to home phototherapy were very good and higher than adherence rates for the oral medication. Side effects of treatment were well tolerated in this small group and did not affect use of the treatment. Home phototherapy with acitretin may be an appropriate option for some patients with extensive psoriasis.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by National Biologic Corporation and Connetics. |
|
| Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Connetics, Roche, Amgen, Biogen, and Genentech. Drs Yentzer, Yelverton, Pearce, Fleischer, and Balkrishnan; Mr Camacho; Ms Makhzoumi; Ms Clark; and Ms Boles have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 59 - N° 4
P. 577-581 - octobre 2008 Retour au numéro
Article précédent
- Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study
- David Pariser, Robert Loss, Michael Jarratt, William Abramovits, James Spencer, Roy Geronemus, Philip Bailin, Suzanne Bruce
- Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States
- Sareeta R.S. Parker, Senait Dyson, Stacey Brisman, Michelle Pennie, Robert A. Swerlick, Rizwana Khan, Sue Manos, Benjamin D. Korman, Zongqi Xia, Neil J. Korman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?